N 0164 | CAS#60787-00-0

MedKoo Cat#: 534875 | Name: N 0164

Description:

WARNING: This product is for research use only, not for human or veterinary use.

N 0164 is a bioactive chemical.

Chemical Structure

N 0164

CAS#60787-00-0

Theoretical Analysis

MedKoo Cat#: 534875

Name: N 0164

CAS#: 60787-00-0

Chemical Formula: C29H25ClNaO4P

Exact Mass: 526.1077

Molecular Weight: 526.93

Elemental Analysis: C, 66.10; H, 4.78; Cl, 6.73; Na, 4.36; O, 12.15; P, 5.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

N 0164; N-0164; N0164

IUPAC/Chemical Name

(Phenylmethyl)phosphonic acid, mono(4-(2-((4-chlorophenyl)methyl)-1-oxo-3-phenylpropyl)phenyl) ester, sodium salt

InChi Key

RIYADZCUQWEJEP-UHFFFAOYSA-M

InChi Code

InChI=1S/C29H26ClO4P.Na/c30-27-15-11-23(12-16-27)20-26(19-22-7-3-1-4-8-22)29(31)25-13-17-28(18-14-25)34-35(32,33)21-24-9-5-2-6-10-24;/h1-18,26H,19-21H2,(H,32,33);/q;+1/p-1

SMILES Code

[O-]P(CC1=CC=CC=C1)(OC2=CC=C(C(C(CC3=CC=C(Cl)C=C3)CC4=CC=CC=C4)=O)C=C2)=O.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 526.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Allan G, Levi R. The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N-0164. J Pharmacol Exp Ther. 1980 Jul;214(1):45-9. PMID: 6993659. 2: Eakins KE, Rajadhyaksha V, Schroer R. Prostaglandin antagonism by sodium p-benzyl-4-[1-oxo-2-(4-chlorobenzyl)-3-phenylpropyl]pheenyl phosphonate (N-0164). Br J Pharmacol. 1976 Nov;58(3):333-9. doi: 10.1111/j.1476-5381.1976.tb07709.x. PMID: 990588; PMCID: PMC1667574. 3: Maas AJ, Den Hertog A. The effect of the phenyl phosphonate N-0164 on prostaglandin action and on post inhibitory excitation in the taenia of guinea- pig caecum. Eur J Pharmacol. 1980 Mar 21;62(2-3):157-66. doi: 10.1016/0014-2999(80)90272-1. PMID: 7379838. 4: Tynan SS, Andersen NH, Wills MT, Harker LA, Hanson SR. On the multiplicity of platelet prostaglandin receptors. II. The use of N-0164 for distinguishing the loci of action for PGI2, PGD2, PGE2 and hydantoin analogs. Prostaglandins. 1984 May;27(5):683-96. doi: 10.1016/0090-6980(84)90007-8. PMID: 6087417. 5: Boyle J, Patronas NJ, Smirniotopoulos J, Herscovitch P, Dieckman W, Millo C, Maric D, Chatain GP, Hayes CP, Benzo S, Scott G, Edwards N, Ray Chaudhury A, Lodish MB, Sharma S, Nieman LK, Stratakis CA, Lonser RR, Chittiboina P. CRH stimulation improves 18F-FDG-PET detection of pituitary adenomas in Cushing's disease. Endocrine. 2019 Jul;65(1):155-165. doi: 10.1007/s12020-019-01944-7. Epub 2019 May 6. PMID: 31062234. 6: Vulliemoz Y, Verosky M, Triner L. Effect of a prostaglandin antagonist, N-0164, on cAMP generation and hydrolysis in the rat uterus. Biochem Pharmacol. 1981 Jul 15;30(14):1941-6. doi: 10.1016/0006-2952(81)90203-3. PMID: 6268114. 7: Botting JH, Linton EA, Whitehead SA. Blockade of ovulation in the rat by a prostaglandin antogonist (N-0164). J Endocrinol. 1977 Nov;75(2):335-6. doi: 10.1677/joe.0.0750335. PMID: 591817. 8: Kulkarni PS, Eakins KE. N-0164 inhibits generation of thromboxane-A2-like activity from prostaglandin endoperoxides by human platelet microsomes. Prostaglandins. 1976 Sep;12(3):465-9. doi: 10.1016/0090-6980(76)90027-7. PMID: 968059. 9: Eakins KE, Kulkarni PS. Selective inhibitory actions of sodium-p- benzyl-4-[1-oxo-2-(4-chlorobenzyl)-3-phenyl propyl] phenyl phosphonate (N-0161) and indomethacin on the biosynthesis of prostaglandins and thromboxanes from arachidonic acid. Br J Pharmacol. 1977 May;60(1):135-40. doi: 10.1111/j.1476-5381.1977.tb16757.x. PMID: 884384; PMCID: PMC1667177. 10: Chatain GP, Patronas N, Smirniotopoulos JG, Piazza M, Benzo S, Ray-Chaudhury A, Sharma S, Lodish M, Nieman L, Stratakis CA, Chittiboina P. Potential utility of FLAIR in MRI-negative Cushing's disease. J Neurosurg. 2018 Sep;129(3):620-628. doi: 10.3171/2017.4.JNS17234. Epub 2017 Oct 13. PMID: 29027863; PMCID: PMC6398169. 11: Hamid-Bloomfield S, Whittle BJ. Prostaglandin D2 interacts at thromboxane receptor-sites on guinea-pig platelets. Br J Pharmacol. 1986 Aug;88(4):931-6. doi: 10.1111/j.1476-5381.1986.tb16268.x. PMID: 3017497; PMCID: PMC1917072. 12: Brus R, Zabawska J. Anagoniści prostaglandyn [Prostaglandin antagonists]. Postepy Hig Med Dosw. 1980 Nov-Dec;33(6):677-91. Polish. PMID: 6104329. 13: Schlicker E, Fink K, Göthert M. Influence of eicosanoids on serotonin release in the rat brain: inhibition by prostaglandins E1 and E2. Naunyn Schmiedebergs Arch Pharmacol. 1987 Jun;335(6):646-51. doi: 10.1007/BF00166981. PMID: 3476858. 14: Manku MS, Horrobin DF, Oka M, Ally AI, Karmazyn M, Cunnane SC, Morgan RO, Karmali RA. Ultra-violet radiation and 8-methoxypsoralen have actions similar to those of known inhibitors of thromboxane A2 synthesis in rat mesenteric blood vessels. Prostaglandins Med. 1978 Jul;1(1):86-95. doi: 10.1016/0161-4630(78)90080-0. PMID: 715050. 15: Hattori Y, Levi R. Effect of PGD2 on cardiac contractility: a negative inotropism secondary to coronary vasoconstriction conceals a primary positive inotropic action. J Pharmacol Exp Ther. 1986 Jun;237(3):719-24. PMID: 3012066. 16: Whittle BJ, Moncada S, Vane JR. Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins. 1978 Sep;16(3):373-88. doi: 10.1016/0090-6980(78)90216-2. PMID: 364545. 17: Kangasaho M, Vapaatalo H. TXA2-antagonistic properties of agents affecting prostaglandin synthesis or the cyclic nucleotide system in human platelets. Acta Pharmacol Toxicol (Copenh). 1983 Aug;53(2):130-4. doi: 10.1111/j.1600-0773.1983.tb01880.x. PMID: 6624480. 18: Seiler S, Brassard CL, Federici ME. SQ-27986 inhibition of platelet aggregation is mediated through activation of platelet prostaglandin D2 receptors. Prostaglandins. 1990 Aug;40(2):119-30. doi: 10.1016/0090-6980(90)90078-a. PMID: 2171039. 19: Kelly JP, Johnson MC, Parker CW. Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: possible role of thromboxanes and products of the lipoxygenase pathway. J Immunol. 1979 Apr;122(4):1563-71. PMID: 109510. 20: Miller OV, Gorman RR. Evidence for distinct prostaglandin I2 and D2 receptors in human platelets. J Pharmacol Exp Ther. 1979 Jul;210(1):134-40. PMID: 221643.